High-dose melphalan-autologous hematopoietic cell transplantation in systemic AL amyloidosis following daratumumab-based frontline therapy

被引：2
|
作者：
Mellgard, George S. [1 ]
Bhutani, Divaya [2 ]
Mapara, Markus Y. [2 ]
Maurer, Mathew S. [3 ]
Radhakrishnan, Jai [4 ]
Lentzsch, Suzanne [2 ]
Chakraborty, Rajshekhar [2 ]
机构：
[1] Columbia Univ, Dept Med, Irving Med Ctr, New York, NY USA
[2] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA
[3] Columbia Univ, Div Cardiol, Irving Med Ctr, New York, NY USA
[4] Columbia Univ, Div Nephrol, Irving Med Ctr, New York, NY USA
来源：
BONE MARROW TRANSPLANTATION | 2024年 / 59卷 / 08期
关键词：
LIGHT-CHAIN AMYLOIDOSIS; DEXAMETHASONE; INHIBITOR;
D O I：
10.1038/s41409-024-02301-7
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：1181 / 1183
页数：3
相关论文
共 50 条
  • [31] Effect of severe hypoalbuminemia on toxicity of high-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis
    Lee, S. Y.
    Meehan, R. S.
    Seldin, D. C.
    Sloan, J. M.
    Quillen, K.
    Shelton, A.
    Brauneis, D.
    Sanchorawala, V.
    BONE MARROW TRANSPLANTATION, 2016, 51 (10) : 1318 - 1322
  • [32] Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis
    V Sanchorawala
    D G Wright
    K Quillen
    K T Finn
    L M Dember
    J L Berk
    G Doros
    C Fisher
    M Skinner
    D C Seldin
    Bone Marrow Transplantation, 2007, 40 : 557 - 562
  • [33] Melphalan and high-dose dexamethasone in patients with AL (primary) amyloidosis ineligible for autologous stem cell transplantation.
    Palladini, G
    Perfetti, V
    Obici, L
    Merlini, G
    BLOOD, 2002, 100 (11) : 397A - 398A
  • [34] Reduced early mortality with Daratumumab-based frontline therapy in AL amyloidosis: A retrospective cohort study
    Chakraborty, Rajshekhar
    Bhutani, Divaya
    Mapara, Markus
    Reshef, Ran
    Maurer, Mathew S.
    Radhakrishnan, Jai
    Lentzsch, Suzanne
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (03) : 477 - 479
  • [35] High-dose therapy and autologous stem cell transplantation (ASCT) for systemic amyloidosis (AL): Report of 9 cases.
    Amoura, Z
    Leblond, V
    Azar, N
    Montalescot, G
    Bagnis, C
    Schmidt, J
    de Gennes, C
    Wechsler, B
    Boccaccio, C
    Godeau, P
    Piette, JC
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S234 - S234
  • [36] High Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation in AL Amyloidosis
    Sanchorawala, Vaishali
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2014, 28 (06) : 1131 - +
  • [37] Timing and outcomes of second-line therapy in the era of daratumumab-based frontline therapy in AL amyloidosis
    Bazarbachi, Abdul-Hamid
    Bhutani, Divaya
    Radhakrishnan, Jai
    Mapara, Markus
    Maurer, Mathew S.
    Lentzsch, Suzanne
    Chakraborty, Rajshekhar
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (11) : 2225 - 2228
  • [38] Hospital admissions following outpatient administration of high-dose melphalan and autologous SCT for AL amyloidosis
    Freeman, B.
    Brauneis, D.
    Seldin, D. C.
    Quillen, K.
    Sloan, J. M.
    Renteria, A. S.
    Shelton, A. C.
    Teschner, T.
    Finn, K. T.
    Sanchorawala, V.
    BONE MARROW TRANSPLANTATION, 2014, 49 (10) : 1345 - 1346
  • [39] Hospital admissions following outpatient administration of high-dose melphalan and autologous SCT for AL amyloidosis
    B Freeman
    D Brauneis
    D C Seldin
    K Quillen
    J M Sloan
    A S Renteria
    A C Shelton
    T Teschner
    K T Finn
    V Sanchorawala
    Bone Marrow Transplantation, 2014, 49 : 1345 - 1346
  • [40] High-dose melphalan followed by autologous stem cell support in primary systemic AL amyloidosis with multiple organ involvement
    Shimojima, Y
    Matsuda, M
    Ishii, W
    Koyama, J
    Yamamoto, K
    Shimodaira, S
    Sakashita, K
    Koike, K
    Ikeda, S
    INTERNAL MEDICINE, 2005, 44 (05) : 484 - 489
12345